Analyst recommendations
LSE: Initially Neutral on the company, UBS’s analyst Michael Werner maintained his recommendation. The target price is reviewed upwards from GBX 7600 to GBX 9000.
Deutsche Boerse: In his latest research note, analyst Michael Werner confirms his positive recommendation. The broker UBS is keeping its Buy rating. The target price has been revised upwards and is now set at EUR 175, compared with EUR 160 previously.
Heidelbergcement: Analyst Gregor Kuglitsch from UBS research considers the stock attractive and recommends it with a Buy rating. Previously set at EUR 60, the target price has been raised to EUR 62.
Siemens: In a research note published by Andreas Willi, JP Morgan advises its customers to buy the stock. The target price is unchanged and still at EUR 126.
Swiss Re: In a research note, Barclays analyst Claudia Gaspari has maintained his recommendation on the stock with a Buy rating. The target price is revised upwards from CHF 96 to CHF 91.
Prudential: Claudia Gaspari from Barclays retains his positive opinion on the stock with a Buy rating. Previously set at GBX 1440, the target price has been raised to GBX 1532.
AXA: In his latest research note, analyst Claudia Gaspari confirms his positive recommendation. The broker Barclays is keeping its Buy rating. Previously set at EUR 25.90, the target price is lowered to EUR 25.50.
Munich Re: Claudia Gaspari from Barclays retains his positive opinion on the stock with a Buy rating. The target price has been revised upwards and is now set at EUR 269, compared with EUR 247 previously.
Allianz: In his latest research note, analyst Claudia Gaspari confirms his recommendation. The broker Barclays is keeping its Neutral rating. The target price has been revised downwards and is now set at EUR 200 as compared to EUR 204 previously.
Carrefour: Already positive, the research from JP Morgan and its analyst Borja Olcese still consider the stock as a Buy opportunity. The target price is still set at EUR 17.
AstraZeneca: JP Morgan is positive on the stock with a Buy rating. The target price is unchanged at GBX 9500.
Glaxosmithkline: JP Morgan’s research confirms his advice and maintains his neutral opinion on the stock. The target price is reduced from GBX 1700 to GBX 1650.